SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics (RR) is trending due to increased investor interest and speculation surrounding its new robot unveiling at an upcoming NVIDIA conference. Community members are actively discussing the potential for a short squeeze, fueled by positive sentiment and anticipation of future deals. With growing excitement around the robotics sector, RR is capturing attention as a key player, especially given its ties to NVIDIA.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the new iPhone release drives optimism, with analysts raising price targets and the community noting strong early demand and long lines. Some traders are riding the wave of momentum, while others express caution about stretched valuations and potential pullbacks. Discussions include the impact of AI features and the competitive landscape within the tech sector.

Boxlight Corp. is a technological company, which engages in developing, selling, and providing interactive classroom solutions for the global education market. It also designs, manufactures, and distributes interactive projectors, flat panel displays, touch projectors, touch boards, and MimioTeach through the Boxlight Group and Genesis brands. The company was founded by Herbert Myers and Sloan Myers in 1985 and is headquartered in Duluth, GA.

Boxlight Corporation - Ordinary Shares - Class A

Boxlight Corp

BOXL is trending due to significant momentum and potential short squeeze, fueled by news of Google EDLA interactive display shipments. Community members are actively discussing locking in gains and speculating on price targets, while noting the stock's low float and high short interest. The stock's volatile price action is also a key talking point.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to speculation around its potential in the weight loss and MASH markets, especially following Pfizer's acquisition of Metsera. The community is actively discussing potential buyout scenarios, comparing VKTX's pipeline and market cap to those of acquired companies, and debating the company's strategic options. Many believe Viking is undervalued and could be an acquisition target for larger pharmaceutical companies looking to expand their portfolios.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending due to significant price volatility and trading halts, sparking discussions around potential short squeezes and the influence of figures like Eric Jackson. Community members are weighing the company's fundamentals, including its cash position and low float, against concerns about dilution and profitability. The stock's movement is also being compared to other real estate and mortgage companies, with some seeing potential for substantial growth.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital ($APLD) is trending as anticipation builds for a potential hyperscaler deal announcement, with the community buzzing about a possible short squeeze and significant gains by year-end. Bullish sentiment is fueled by existing AI data center contracts and expansion plans, leading to speculation about future partnerships and revenue growth. The stock's strong performance and ties to the AI infrastructure boom are also driving investor interest.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as the community discusses its potential in the drone sector, especially after news of a public offering to fund its unmanned surface vessel division; the community sees the funding as a move to capitalize on anticipated government contracts and expand into new markets, with some debating its market cap relative to competitors like Ondas. Talk about NATO contracts and comparisons to other drone stocks are circulating.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target ($TGT) is trending as it approaches multi-year lows, sparking debate about a potential value play versus a value trap. Community members are discussing TRC Capital’s mini-tender offer and concerns over sales and foot traffic, while some bulls are hopeful for a bounce driven by the dividend yield or even Taylor Swift's upcoming album.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

BKKT is trending as investors discuss the appointment of Mike Alfred to the board, speculating on the potential impact on the company's growth strategy, especially in digital assets and AI. Community members are also focused on the possibility of a short squeeze and the company's debt-free status. Some see a potential connection to a broader crypto or fintech play.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as discussions revolve around its agentic AI and automation products driving revenue growth and the company's attractive valuation despite strong cash reserves. Community members highlight the company's accelerating revenue growth, improved margins, and raised guidance, viewing it as undervalued compared to competitors like Palantir. Some are speculating about a potential acquisition, while others focus on the company's potential for a short squeeze due to high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MBX Biosciences, Inc. (MBX) said on Monday that its once-weekly Canvuparatide achieved the primary endpoint with statistical significance at week 12 in its mid-stage trial in adult patients with chronic hypoparathyroidism.Hypoparathyroidism is a rare endocrine disease caused by a deficiency of parathyroid hormone (PTH) released by the parathyroid glands that results in decreased calcium levels in the blood. According to MBX, the disease affects more than 250,000 individuals in the U.S. and Europe.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-once-weekly-canvuparatide-achieved">noted</a> that 63% of Canvuparatide-treated patients in the study maintained serum calcium levels within the normal range and were independent of conventional therapy, including active vitamin D and calcium supplements, at week 12, with zero contribution from rescue therapy, compared to 31% in placebo-treated patients, the company stated.In the open-label extension of the trial, 79% of patients who received treatment achieved these milestones at six months. The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.Shares of the company soared 144% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MBX">MBX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.Guggenheim subsequently raised its price target on MBX to $84 from $44 while keeping a ‘Buy’ rating on the shares. The results achieved the firm's "bull case," noted the analyst, who increased the firm's view of the odds of success for Canvuparatide to 75% from 50% previously. Guggenheim also argued that the data provides "clear line of sight to blockbuster-plus potential."CEO Kent Hawryluk said that the company is pleased with the results. “We believe the totality of the data support a once-weekly product profile with continuous infusion-like PTH exposure. These 12-week and 6-month results represent the potential for a meaningful improvement over current treatment options for HP patients and provide a strong foundation for further development,” he said.All doses of Canvuparatide were generally well-tolerated with no discontinuations related to the drug, and no treatment-related serious adverse events or discontinuations were recorded during the 12-week trial, the company said.MBX stock is down 46% this year and approximately 55% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-shareholder-yunqi-capital-opposes-proposed-merger-with-alcon/chDQFDHR32a">STAAR Surgical’s Shareholder Yunqi Capital Opposes Proposed Merger With Alcon – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study

The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.

Equity

The company is now preparing to kickstart a late-stage trial of once-weekly Canvuparatide in 2026.


These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

MBX Biosciences Inc.

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

MBX
MBX Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MBX News

MBX MBX Biosciences Inc.